In this work, they were able to assess that, while the majority of metastases do not present significant inflammatory infiltrates and lack PD1, PD-L1, and CTLA4 (targets recently evaluated in clinical trials), the B7-H3/CD276 immune checkpoint protein was highly expressed, particularly in those cancers with high AR activity [18]. This evidence concerns the gene CD276 and cancer.